CARDIOVASCULAR
hamburger
BACK
Momentum 3 Long-Term Cohort

MOMENTUM 3 LONG-TERM COHORT

366 PATIENTS FOLLOWED FOR TWO YEARS

Two-Year Primary Outcomes in the MOMENTUM 3 Long-Term Cohort

Mehra, M.R., Goldstein, D.J., Uriel, N., Cleveland, J.C., Yuzefpolskaya, M., Salerno, C., …, Naka, Y., for the MOMENTUM 3 Investigators. (2018). Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med, 378(15), 1386-95. https://www.doi.org/10.1056/NEJMoa1800866

The data from the two-year MOMENTUM 3 trial pre-specified primary analysis demonstrates:

  • Durability of the HeartMate 3 LVAS to optimally support patients who wait for extended periods for heart transplantation or are ineligible for heart transplantation (destination therapy).
  • Clinical superiority of the HeartMate 3 LVAS when compared to the HeartMate II LVAS axial-flow pump.
  • Lowest published rates for both stroke and pump thrombosis at 2 years.
  • Lower rate of reoperation for pump malfunction in the HeartMate 3 LVAS arm.
View Article Download Presentation

Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Cohort

Mehra, M.R., Salerno, C., Cleveland, J.C., Pinney, S., Yuzefpolskaya, M., Milano, C. A., ... Silvestry, S.C. (2018)Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure. Circulation, 138(18), 1923-34. https://doi.org/10.1161/CIRCULATIONAHA.118.035722

In this two-year economic analysis of the MOMENTUM 3 trial, the HeartMate 3 LVAS in comparison with the HeartMate II LVAS demonstrated:

  • Reduction in rehospitalizations.
  • Reduction in hospital days spent during rehospitalizations.
  • Cost savings following discharge.
View Article Download Presentation

Comprehensive Analysis of Stroke in the MOMENTUM 3 Long-Term Cohort

Colombo, P.C., Mehra, M.R., Goldstein, D.J., Estep, J.D., Salerno, C., Jorde, U.P., … Horstmanshof, D.A. (2019). Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump. Circulation, 139 (2), 155-168. https://doi.org/10.1161/CIRCULATIONAHA.118.037231

This comprehensive stroke analysis of the long-term cohort of the MOMENTUM 3 study shows the following:

  • In patients with advanced heart failure, the use of the HeartMate 3 LVAS lowers stroke rates when compared with the HeartMate II LVAS pump.
  • The occurrence of stroke of any type or any functional severity is predictive of a poor two-year clinical outcome.
View Article Download Presentation

MAT-2006846 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno